Levi Josefsson, MT-BC in Orem, UT - Music Therapist

Levi Josefsson, MT-BC is a Music Therapist based in Orem, Utah. Levi Josefsson is licensed to practice in * (Not Available) (license number ) and his current practice location is 2066 W 885 S, Orem, Utah. He can be reached at his office (for appointments etc.) via phone at (310) 748-9271.

NPI number for Levi Josefsson is 1023704632 and his current mailing address is 2066 W 885 S, Orem, Utah. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1023704632.

Contact Information

	Levi Josefsson, MT-BC
	2066 W 885 S, Orem, UT 84059-5596
	(310) 748-9271
	Not Available

Healthcare Provider's Profile

Full Name	Levi Josefsson
Gender	Male
Speciality	Music Therapist
Location	2066 W 885 S, Orem, Utah
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1023704632
Provider Enumeration Date: 04/17/2023
Last Update Date: 04/17/2023

Medical Identifiers

Medical identifiers for Levi Josefsson such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1023704632	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
106H00000X	Marriage & Family Therapist	(* (Not Available))	Secondary
225A00000X	Music Therapist	(* (Not Available))	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Levi Josefsson is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Levi Josefsson, MT-BC 2066 W 885 S, Orem, UT 84059-5596 Ph: (310) 748-9271	Levi Josefsson, MT-BC 2066 W 885 S, Orem, UT 84059-5596 Ph: (310) 748-9271

News Archive

Ocugen's OCU100 gets FDA orphan drug designation for treatment of retinitis pigmentosa

Ocugen, Inc. and the University of Colorado today announced exclusive license agreements that allow for Ocugen to continue developing two drug candidates for the treatment for ophthalmology indications, and that one of the assets, OCU100, recombinant lens epithelium derived growth factor 1-326 (LEDGF1-326), received orphan-drug status from the U.S. Food and Drug Administration for treatment of retinitis pigmentosa (RP), a rare eye disease.

Pharmacor 2010 findings predict COPD drug market rise to $13 billion in 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, through 2019, an expanding aging population and increases in diagnosis and drug treatment will fuel steady 4.6 percent annual growth in the chronic obstructive pulmonary disease (COPD) drug market.

Small-molecule drug improves brain performance in mouse model of Rett syndrome

After learning that a small-molecule drug improves breathing in a mouse model of the neurodevelopmental disorder Rett syndrome, University of Alabama at Birmingham researcher Lucas Pozzo-Miller, Ph.D., wondered if he could test it on other brain functions.

Viewpoints: 'Thrice-buried' Obamacare 'looks very much alive;' Ted Cruz 'gets an earful'

Back when rate shock, website problems and lagging enrollment were threatening to unravel the new health care law before it fully took effect, I concluded a column on Obamacare's repeated near-death experiences with the following warning to conservatives: ... What isn't killed outright grows stronger the longer it's embedded in the federal apparatus, gaining constituents and interest-group support just by virtue of its existence even if it doesn't work out the way it was designed. ... the serious right-of-center alternatives to Obamacare have always included policies to expand coverage, and with a coverage expansion accomplished, Republicans may find themselves effectively forced in a more serious direction. ... wherever they go and whatever they do, they will have to deal with the reality that Obamacare, thrice-buried, looks very much alive (Ross Douthat, 3/31).

Prior parasitic worm infections may complicate TB therapy

Tuberculosis (TB) is a major threat to global health, taking the lives of more than a million people worldwide each year. Its greatest impact is often in the most impoverished places on earth, where patients frequently suffer from multiple chronic illnesses at the same time. In such situations, the question of whether each individual illness might make concurrent illnesses more difficult to treat becomes a critical issue both for specific patients and for general public health.

Levi Josefsson, MT-BC - Couples Therapy in Orem, UT